NY-THE-BODY-SHOP
11.5.2022 17:02:10 CEST | Business Wire | Press release
Millions of young people are missing from public life. With the climate crisis, global conflict and generational inequalities running rampant, the inputs, perspectives and representation of youth are needed more than ever.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220509005499/en/
Almost half the world's population is under 30. Yet, they make up only 2.6% of parliamentarians around the world**. The average age of a world leader is currently 62***. Of all the parliaments in the world, 37% do not have a single Member of Parliament (MP) under age 30** and less than 1% of these young MPs are women.
Young people have the right to be included in political decisions that affect them, however, numerous barriers prevent their participation. The Body Shop and the Office of the United Nations Secretary-General's Envoy on Youth are collaborating to change this through the global Be Seen Be Heard campaign, which seeks to create long-term structural changes to decision-making to be more inclusive of young people.
It is launched today with the release of a research piece titled ‘ Be Seen Be Heard: Understanding young people’s political participation’.
The research includes the largest-ever survey carried out by The Body Shop, covering 26 countries with 27,043 respondents. It found that 82% of people surveyed agree that political systems need drastic reform to be fit for the future.
Two in three people also agree that the age balance in politics is wrong, with 8 in 10 people of all ages believing the ideal voting age (the age when someone can first vote) is 16 to 18, despite that in most countries the voting age is 18 or over. A third of those under age 30 surveyed would consider running for office versus only a fifth of those over age 30. People across all age groups agree that more opportunities for younger people to have a say in policy development and/or change would make political systems better.
David Boynton, CEO of The Body Shop says, “Our position is clear. The world’s problems cannot be solved by the same people making the same choices. The majority of young people are positive about the future, and we need to hear their views and ideas inside the halls of power. We will use our global reach to galvanise awareness and support, as we have in the past.”
Jayathma Wickramanayake, the United Nations Secretary-General’s Envoy on Youth says, “The intergenerational gap in power, influence and trust constitutes one of the biggest challenges of our time. Participation is a right, and a lack of youth representation where decisions are made contributes to a growing mistrust towards political institutions and a sense of alienation from elected leaders, caused by policies that do not reflect the priorities of youth, mirror their concerns or speak their language. This campaign is an opportunity to change that.”
The report suggests that young people’s participation in public decision-making could be improved long-term by a number of initiatives including; lowering voting ages, increasing formal youth representation, removing barriers for young people to participate in public decision-making, simplifying registration for first-time voters and improving young people’s leadership skills.
The campaign is launching globally in May 2022 and will run until mid-2025, driven by action in over 2,600 Body Shop stores in 75 countries, across six continents.
More information here.
Ends
** https://www.ipu.org/our-impact/youth-empowerment/data-youth-participation
*** REIGN Dataset | REIGN (oefdatascience.github.io)
View source version on businesswire.com: https://www.businesswire.com/news/home/20220509005499/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
